Indaptus Therapeutics, a preclinical biotechnology company based in New York City, focuses on multi-targeted immune system activation using a Decoy platform for anti-tumor and anti-viral responses. Its lead candidate, Decoy20, shows promise against chronic HBV and HIV infections.
Indaptus Therapeutics (INDP) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Indaptus Therapeutics's actual EPS was -$8.96, missing the estimate of -$5.14 per share, resulting in a -74.29% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
